169 related articles for article (PubMed ID: 31596021)
1. Exploration of imidazole and imidazopyridine dimers as anticancer agents: Design, synthesis, and structure-activity relationship study.
Meenakshisundaram S; Manickam M; Pillaiyar T
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900011. PubMed ID: 31596021
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure--activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents.
Sajith AM; Abdul Khader KK; Joshi N; Reddy MN; Syed Ali Padusha M; Nagaswarupa HP; Nibin Joy M; Bodke YD; Karuvalam RP; Banerjee R; Muralidharan A; Rajendra P
Eur J Med Chem; 2015 Jan; 89():21-31. PubMed ID: 25462222
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of imidazopyridine-linked thiazolidinone as potential anticancer agents.
Iqbal MA; Husain A; Alam O; Khan SA; Ahmad A; Haider MR; Alam MA
Arch Pharm (Weinheim); 2020 Oct; 353(10):e2000071. PubMed ID: 32627909
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
9. Novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives: Design, synthesis, antiproliferative activity and DNA/RNA binding study.
Lončar B; Perin N; Mioč M; Boček I; Grgić L; Kralj M; Tomić S; Stojković MR; Hranjec M
Eur J Med Chem; 2021 May; 217():113342. PubMed ID: 33751978
[TBL] [Abstract][Full Text] [Related]
10. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of 2-(3,4-dimethoxyphenyl)-6 (1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridine analogues as antiproliferative agents.
Chitti S; Singireddi S; Santosh Kumar Reddy P; Trivedi P; Bobde Y; Kumar C; Rangan K; Ghosh B; Sekhar KVGC
Bioorg Med Chem Lett; 2019 Sep; 29(18):2551-2558. PubMed ID: 31420269
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
13. Effective synthesis of benzimidazoles-imidazo[1,2-a]pyrazine conjugates: A comparative study of mono-and bis-benzimidazoles for antitumor activity.
Singh I; Luxami V; Paul K
Eur J Med Chem; 2019 Oct; 180():546-561. PubMed ID: 31344614
[TBL] [Abstract][Full Text] [Related]
14. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Yang Y; Zhang Y; Yang L; Zhao L; Si L; Zhang H; Liu Q; Zhou J
Bioorg Chem; 2017 Feb; 70():126-132. PubMed ID: 28043720
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor compounds identification from gossypol Groebke imidazopyridine product.
Wang W; Lu Y; Chen E; Shen K; Li J
Bioorg Chem; 2021 Sep; 114():105146. PubMed ID: 34328859
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
Liu TC; Peng X; Ma YC; Ji YC; Chen DQ; Zheng MY; Zhao DM; Cheng MS; Geng MY; Shen JK; Ai J; Xiong B
Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
[TBL] [Abstract][Full Text] [Related]
17. Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation.
El-Naggar M; Almahli H; Ibrahim HS; Eldehna WM; Abdel-Aziz HA
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914120
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and cytotoxic activities of novel hybrid compounds between 2-phenylbenzofuran and imidazole.
Yang XD; Wan WC; Deng XY; Li Y; Yang LJ; Li L; Zhang HB
Bioorg Med Chem Lett; 2012 Apr; 22(8):2726-9. PubMed ID: 22440627
[TBL] [Abstract][Full Text] [Related]
19. Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1.
Su JC; Chang CH; Wu SH; Shiau CW
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1248-1255. PubMed ID: 30261753
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.
Krause M; Foks H; Gobis K
Molecules; 2017 Mar; 22(3):. PubMed ID: 28273868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
